Jason Coloma Sells 25,582 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 25,582 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $26.02, for a total value of $665,643.64. Following the completion of the sale, the chief executive officer owned 350,987 shares in the company, valued at $9,132,681.74. This trade represents a 6.79% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Trading Up 1.3%

Shares of Maze Therapeutics stock opened at $26.40 on Friday. Maze Therapeutics, Inc. has a 1 year low of $9.73 and a 1 year high of $53.65. The firm has a market cap of $1.46 billion, a PE ratio of -10.43 and a beta of 2.50. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.88 and a quick ratio of 17.88. The company has a 50 day simple moving average of $29.21 and a two-hundred day simple moving average of $37.59.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The business had revenue of $20.00 million for the quarter. Analysts expect that Maze Therapeutics, Inc. will post -2.74 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Guggenheim raised their price target on Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Truist Financial decreased their target price on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a research note on Tuesday, April 14th. JPMorgan Chase & Co. lifted their target price on shares of Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 31st. Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, HC Wainwright boosted their price target on Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $66.00.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Washington University increased its holdings in Maze Therapeutics by 33.3% during the 4th quarter. Washington University now owns 280,802 shares of the company’s stock valued at $11,634,000 after purchasing an additional 70,121 shares during the period. Mass General Brigham Inc purchased a new position in Maze Therapeutics during the 4th quarter valued at about $9,943,000. ArrowMark Colorado Holdings LLC bought a new stake in Maze Therapeutics during the 3rd quarter valued at approximately $14,135,000. Boothbay Fund Management LLC boosted its position in Maze Therapeutics by 365.9% during the 3rd quarter. Boothbay Fund Management LLC now owns 351,875 shares of the company’s stock valued at $9,124,000 after acquiring an additional 276,345 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in Maze Therapeutics by 27.1% during the 4th quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company’s stock valued at $70,307,000 after acquiring an additional 362,060 shares in the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.